Skip to main content
SpringerLink
Log in
Book cover

Oral Pharmacotherapy for Male Sexual Dysfunction pp 199–220Cite as

Erectile Dysfunction

Assessing Risk and Managing the Cardiac Patient

  • Chapter

Part of the book series: Current Clinical Urology ((CCU))

Abstract

“Is impotence an arterial disorder?” When Virag et al. (1) asked this question in their Lancet article in 1985, an important association between atherogenic risk factors and erectile dysfunction (ED) was brought to our attention. In 440 men with ED, atherogenic risk factors were significantly more common than in a male population of similar age. Smoking (64%), diabetes mellitus (30%), and hyperlipidemia (34%) were the most common risk factors associated with ED.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Virag R, Bouilly P, Frydman D. (1985) Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1:181–184.

    Article  PubMed  CAS  Google Scholar 

  2. Johannes CB, Araujo AB, Feldman HA, et al. (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 163:460–463.

    Article  PubMed  CAS  Google Scholar 

  3. Feldman HA, Goldstein I, Hatzichristou DG, et al. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61.

    PubMed  CAS  Google Scholar 

  4. Walczak MK, Lokhandwala N, Hodge MB, et al. (2002) Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 6:19–21.

    Google Scholar 

  5. Kloner RA, Mullin SH, Shook T, et al. (2003) Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 170:S46–S50.

    Article  PubMed  Google Scholar 

  6. Levine LA, Kloner RA. (2000) Importance of asking questions about erectile dysfunction. Am J Cardiol 86:1210–1213.

    Article  PubMed  CAS  Google Scholar 

  7. Baldwin K, Ginsberg P, Harkaway RC. (2003) Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res 15:87–89.

    Article  PubMed  CAS  Google Scholar 

  8. O’Kane PD, Jackson G. (2001) Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract 55:219–220.

    PubMed  CAS  Google Scholar 

  9. Levine LA. (2000) Diagnosis and treatment of erectile dysfunction. Am J Med. 109:3S–12S.

    Article  PubMed  Google Scholar 

  10. Benet AE, Melman A. (1995) The epidemiology of erectile dysfunction. Urol Clin North Am 22:699–709.

    PubMed  CAS  Google Scholar 

  11. Greiner KA, Weigel JW. (1996) Erectile dysfunction. Am Fam Physician 54:1675–1682.

    PubMed  CAS  Google Scholar 

  12. Kloner RA, Speakman M. (2002) Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 4:397–401.

    Article  PubMed  Google Scholar 

  13. Nicolosi A, Moreira ED, Shirai M, et al. (2003) Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 61:201–206.

    Article  PubMed  Google Scholar 

  14. NIH Consensus Development Panel on Impotence. (1993) Impotence. JAMA 270: 83–90.

    Article  Google Scholar 

  15. Nusbaum MR. (2002) Erectile dysfunction: prevalence, etiology, and major risk factors. J Am Osteopath Assoc 102:S1–S6.

    PubMed  Google Scholar 

  16. McVary KT, Carrier S, Wessells H, Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. (2001) Smoking and erectile dysfunction: evidence based analysis. J Urol 166: 1624–1632.

    Article  PubMed  CAS  Google Scholar 

  17. Brock GB, Lue TF. (1993) Drug-induced male sexual dysfunction. An update. Drug Saf 8:414–426.

    PubMed  CAS  Google Scholar 

  18. Keene LC, Davies PH. (1999) Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 18:5–24.

    PubMed  CAS  Google Scholar 

  19. Nurnberg HG, Hensley PL, Gelenberg AJ, et al. (2003) Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 289:56–64.

    Article  PubMed  CAS  Google Scholar 

  20. Roth A, Kalter-Leibovici O, Kerbis Y. et al. (2003) Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1412 Israeli men. Clin Cardiol 26:25–30.

    Article  PubMed  Google Scholar 

  21. Moulik PK, Hardy KJ. (2003) Hypertension, anti-hypertensive drug therapy and erectile dysfunction in diabetes. Diabet Med 20:290–293.

    Article  PubMed  CAS  Google Scholar 

  22. Kloner RA, Jarow JP. (1999) Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 83:576–582.

    Article  PubMed  CAS  Google Scholar 

  23. Kim SW, Paick J, Park DW, et al. (2001) Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology 58:441–445.

    Article  PubMed  CAS  Google Scholar 

  24. Solomon H, Man J, Wierzbicki AS, et al. (2003) Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract 57:96–99.

    PubMed  CAS  Google Scholar 

  25. Sairam K, Kulinskaya E, Boustead GB, et al. (2001) Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int 88:68–71.

    Article  PubMed  CAS  Google Scholar 

  26. Boyce EG, Umland EM. (2001) Sildenafil citrate: a therapeutic update. Clin Ther 23:2–23.

    Article  PubMed  CAS  Google Scholar 

  27. Levine SB. (2003) Erectile dysfunction: why drug therapy isn’t always enough. Cleve Clin J Med 70:241–246.

    Article  PubMed  Google Scholar 

  28. Dorey G. (2001) Is smoking a cause of erectile dysfunction? A literature review. Br J Nurs 10:455–465.

    PubMed  CAS  Google Scholar 

  29. Jeremy JY, Mikhailidis DP. (1998) Cigarette smoking and erectile dysfunction. J R Soc Health 118:151–155.

    PubMed  CAS  Google Scholar 

  30. Mirone V, Imhimbo C, Bortolotti A, et al. (2002) Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study. Eur Urol 41:294–297.

    Article  PubMed  Google Scholar 

  31. Romeo JH, Seftel AD, Madhum ZT, et al. (2000) Sexual function in men with diabetes type 2: association with glycemic control. J Urol 163:788–791.

    Article  PubMed  CAS  Google Scholar 

  32. Hale TM, Okabe H, Heaton JP, et al. (2001) Antihypertensive drugs induce structural remodeling of the penile vasculature. J Urol 166:739–745.

    Article  PubMed  CAS  Google Scholar 

  33. Langford HG, Rockfold RW, Wassertheil-Smoller S, et al. (1989) Effect of weight loss on thiazide produced erectile problems in men. Trans Am Clin Climatol Assoc 101:190–194.

    PubMed  CAS  Google Scholar 

  34. Carvajal A, Lerida MT, Sanchez A, et al. (1995) ACE inhibitors and impotence: a case series from the Spanish drug monitoring system. Drug Saf 13:130–131.

    PubMed  CAS  Google Scholar 

  35. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. (2001) Sexual dysfunction in hypertensive patients treated with lorsatan. Am J Med Sci 321:336–341.

    Article  PubMed  CAS  Google Scholar 

  36. Ralph D, McNicholas T, for Erectile Dysfunction Alliance. (2000) UK management guidelines for erectile dysfunction. BMJ 321:499–503.

    Article  PubMed  CAS  Google Scholar 

  37. Rizvi K, Hampson JP, Harvey JN. (2002) Do lipid-lowering drugs cause erectile dysfunction? A system review. Fam Pract 19:95–98.

    Article  PubMed  Google Scholar 

  38. Schachter M. (2000) Erectile dysfunction and lipid disorders. Curr Med Res Opin 16:S9–S12.

    Article  PubMed  Google Scholar 

  39. Bruckert E, Giral P, Heshmati HM, et al. (1996) Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 21: 89–94.

    Article  PubMed  CAS  Google Scholar 

  40. Derby CA, Mohr BA, Goldstein I, et al. (2000) Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 56:302–306.

    Article  PubMed  CAS  Google Scholar 

  41. Pitt B, Remme W, Zannad F, et al. (2003) Eplerone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321.

    Article  PubMed  CAS  Google Scholar 

  42. Pitt B, Zannad F, Remme WJ, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  43. Laumann EO, Paik A, Rosen RC, et al. (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281:537–544.

    Article  PubMed  CAS  Google Scholar 

  44. Sjorgen K, Fugl-Meyer AR. (1983) Some factors influencing quality of sexual life after myocardial infarction. Int Rehabil Med 5:197–201.

    Google Scholar 

  45. Jackson G. (2000) Sexual intercourse and stable angina pectoris. Am J Cardiol 86: 35F–37F.

    Article  PubMed  CAS  Google Scholar 

  46. Jackson G. (1997) Stable angina: drugs, angioplasty or surgery? Eur Heart J 18: B2–B10.

    Article  PubMed  CAS  Google Scholar 

  47. Bohlen JG, Held JP, Sanderson MO, et al. (1984) Heart rate, rate-pressure product and oxygen uptake during four sexual activities. Arch Intern Med 144:1745–1748.

    Article  PubMed  CAS  Google Scholar 

  48. DeBusk RF. (2000) Evaluating the cardiovascular tolerance for sex. Am J Cardiol 86:30F–56F.

    Google Scholar 

  49. Larson JL, McNaughton MW, Kennedy JW, et al. (1980) Heart rate and blood pressure response to sexual activity and a stair-climbing test. Heart Lung 9:1025–1030.

    PubMed  CAS  Google Scholar 

  50. Cheitlin MD, Hutter AM, Brindis RG, et al. (1999) Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 33:273–282.

    Article  PubMed  CAS  Google Scholar 

  51. Ueno M. (1963) The so-called coition death. Jpn J Leg Med 17:330–335.

    CAS  Google Scholar 

  52. DeBusk R, Drory Y, Goldstein I, et al. (2000) Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 86:175–181.

    Article  PubMed  CAS  Google Scholar 

  53. Muller JE, Mittleman MA, Maclure M, et al. (1996) Triggering myocardial infarction by sexual activity. JAMA 275:1405–1409.

    Article  PubMed  CAS  Google Scholar 

  54. DeBusk RF. (1996) Sexual activity triggering myocardial infarction: one less thing to worry about. JAMA 275:1447–1448.

    Article  PubMed  CAS  Google Scholar 

  55. Stein RA. (1977) The effect of exercise training on heart rate during sexual activity in the post-myocardial infarction patient. Circulation 55:738–740.

    PubMed  CAS  Google Scholar 

  56. Jackson G. (1999) Erectile dysfunction and cardiovascular disease. Int J Clin Prac 53:363–368.

    CAS  Google Scholar 

  57. Drory Y, Fisman EZ, Shapira Y, et al. (1996) Ventricular arrhythmias during sexual activity in patients with coronary artery disease. Chest 109:922–924.

    PubMed  CAS  Google Scholar 

  58. Kloner RA. (2000) Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am J Med 109:13S–21S.

    Article  PubMed  Google Scholar 

  59. Arruda-Olson AM, Pellikka PA. (2003) Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction. Herz 28:291–297.

    PubMed  Google Scholar 

  60. Feenstra J, van Drie-Pierik RJ, Lacle CF, et al. (1998) Acute myocardial infarction associated with sildenafil. Lancet 352:957–958.

    Article  PubMed  CAS  Google Scholar 

  61. Zusman RM, Morales A, Glasser DB, et al. (1999) Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83:35C–44C.

    Article  PubMed  CAS  Google Scholar 

  62. Kloner RA. (2000) Cardiovascular risk and sildenafil. Am J Cardiol 86:57F.

    Article  PubMed  CAS  Google Scholar 

  63. Padma-Nathan H, Eardley I, Kloner RA, et al. (2002) A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 60:67–90.

    Article  PubMed  Google Scholar 

  64. Reffelmann T, Kloner RA. (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239–244.

    Article  PubMed  Google Scholar 

  65. Reffelmann T, Kloner RA. (2003) Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 59:441–449.

    Article  PubMed  CAS  Google Scholar 

  66. Morales A, Gingell C, Collins M, et al. (1998) Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 10:69–73; discussion 73,74.

    Article  PubMed  CAS  Google Scholar 

  67. Wysowski DK, Farinas E, Swartz L. (2002) Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 89:1331–1334.

    Article  PubMed  CAS  Google Scholar 

  68. Kloner RA, Mohan P, Norenberg C, et al. (2002) Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction: an analysis of five placebo-controlled clinical trials. Pharmacotherapy 22:1371–1376.

    Google Scholar 

  69. Gresser U, Gleiter CH. (2002) Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Review of the literature. Eur J Med Res 7:435–446.

    PubMed  CAS  Google Scholar 

  70. Corbin JD. (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56:453–459.

    PubMed  CAS  Google Scholar 

  71. Vardi Y, Klein L, Nassar S, et al. (2002) Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 59:747–752.

    Article  PubMed  Google Scholar 

  72. Kloner RA, Brown M, Prisant LM, et al. (2001) Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 14:70–73.

    Article  PubMed  CAS  Google Scholar 

  73. Nichols DJ, Muirhead GJ, Harness JA, et al. (2002) Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53:5S–12S.

    Article  PubMed  CAS  Google Scholar 

  74. Muirhead GJ, Wilner K, Colburn W, et al. (2002) The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Pharmacol 53: 21S–30S.

    Article  CAS  Google Scholar 

  75. Berkels R, Klotz T, Sticht G, et al. (2001) Modulation of human platelet aggregation by the phosphodiesterase 5 inhibitor sildenafil. J Cardiovasc Pharmacol 37: 413–421.

    Google Scholar 

  76. Montorsi F. (2003) Tolerability and safety of apomorphine SL (Ixense). Int J Impot Res 15:S7–S9.

    Article  PubMed  CAS  Google Scholar 

  77. Fagan TC, Buttler S, Marbury T, et al. (2001) Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 88:760–766.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Cardiology, The Heart Institute, Good Samaritan Hospital, Keck School of Medicine, University of Southern California, Los Angeles, CA

    Thorsten Reffelmann MD & Robert A. Kloner MD, PhD

Authors
  1. Thorsten Reffelmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Kloner MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Mayo Clinic College of Medicine, Jacksonville, FL

    Gregory A. Broderick MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Reffelmann, T., Kloner, R.A. (2005). Erectile Dysfunction. In: Broderick, G.A. (eds) Oral Pharmacotherapy for Male Sexual Dysfunction. Current Clinical Urology. Humana Press. https://doi.org/10.1385/1-59259-871-4:199

Download citation

  • DOI: https://doi.org/10.1385/1-59259-871-4:199

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-451-7

  • Online ISBN: 978-1-59259-871-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation